18.09.09 07:40 Age: 174 days
Results for the first half of 2009
Category: Investors
Buoyant growth in activity: +111%
Another half of significant achievements: strengthening of the product portfolio and record sales growth in the United States
Marseille, 18 September 2009 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a cancer ‘profiler’ that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, today announces its consolidated half-year results for its first half to 30 June 2009.
More info
